https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Rhinitis in pregnant women with asthma is associated with poorer asthma control and quality of life https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26396 2.5), moderate/severe versus mild (VAS>6 vs <5), atopic versus non-atopic and pregnancy rhinitis. At baseline, women completed the 20-Item Sino-Nasal Outcome Test (SNOT20), asthma-specific (AQLQ-M) QoL questionnaires and the Six-Item Short-Form State Trait Anxiety Inventory (STAI-6). Asthma control was assessed using the asthma control questionnaire (ACQ). Perinatal outcomes were collected after delivery. Results: Current rhinitis was present in 142 (65%) women including 45 (20%) women who developed pregnancy rhinitis. Women with current rhinitis had higher scores for ACQ (p=0.004), SNOT20 (p<0.0001) and AQLQ-M (p<0.0001) compared to women with no rhinitis. Current rhinitis was associated with increased anxiety symptoms (p=0.002), rhinitis severity was associated with higher ACQ score (p=0.004) and atopic rhinitis was associated with poorer lung function (p=0.037). Rhinitis symptom severity improved significantly during gestation (p<0.0001). There was no impact on perinatal outcomes. Improved asthma control was associated with improvement in rhinitis. Conclusion: Rhinitis in pregnant women with asthma is common and associated with poorer asthma control, sino-nasal and asthma-specific QoL impairment and anxiety. In the context of active asthma management there was significant improvement in rhinitis symptoms and severity as pregnancy progressed.]]> Wed 11 Apr 2018 17:22:04 AEST ]]> Decision support for fetal gestation age estimation https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:2816 Wed 11 Apr 2018 17:19:12 AEST ]]> Human uterine wall tension trajectories and the onset of parturition https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9498 Wed 11 Apr 2018 09:24:59 AEST ]]> Psychosocial variables are related to future exacerbation risk and perinatal outcomes in pregnant women with asthma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14595 Wed 04 Sep 2019 11:33:48 AEST ]]> Neonatal neurodevelopmental outcomes following tocolysis with glycerol trinitrate patches https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:1118 Sat 24 Mar 2018 08:32:00 AEDT ]]> Psychosocial outcomes are related to asthma control and quality of life in pregnant women with asthma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14782 Sat 24 Mar 2018 08:26:30 AEDT ]]> Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17973 ENO) to guide management are equivocal. We tested the hypothesis that a management algorithm for asthma in pregnancy based on FENO and symptoms would reduce asthma exacerbations. Methods: We undertook a double-blind, parallel-group, controlled trial in two antenatal clinics in Australia. 220 pregnant, non-smoking women with asthma were randomly assigned, by a computer-generated random number list, before 22 weeks’ gestation to treatment adjustment at monthly visits by an algorithm using clinical symptoms (control group) or FENO concentrations (active intervention group) used to uptitrate (FENO >29 ppb) or downtitrate (FENO <16 ppb) inhaled corticosteroid dose. Participants, caregivers, and outcome assessors were masked to group assignment. Longacting β2 agonist and minimum dose inhaled corticosteroid were used to treat symptoms when FENO was not increased. The primary outcome was total asthma exacerbations (moderate and severe). Analysis was by intention to treat. This study is registered with the Australian and New Zealand Clinical Trials Registry, number 12607000561482. Findings: 111 women were randomly assigned to the FENO group (100 completed) and 109 to the control group (103 completed). The exacerbation rate was lower in the FENO group than in the control group (0·288 vs 0·615 exacerbations per pregnancy; incidence rate ratio 0·496, 95% CI 0·325–0·755; p=0·001). The number needed to treat was 6. In the FENO group, quality of life was improved (score on short form 12 mental summary was 56·9 [95% CI 50·2–59·3] in FENO group vs 54·2 [46·1–57·6] in control group; p=0·037) and neonatal hospitalisations were reduced (eight [8%] vs 18 [17%]; p=0·046). Interpretation: Asthma exacerbations during pregnancy can be significantly reduced with a validated FENO-based treatment algorithm.]]> Sat 24 Mar 2018 07:56:43 AEDT ]]> Trends in the use of epidural analgesia in Australia https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5070 Sat 24 Mar 2018 07:48:45 AEDT ]]> Longitudinal Analysis of Lung Function in Pregnant Women with and without Asthma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49544 Mon 22 May 2023 08:45:35 AEST ]]> Factors Associated with Asthma Exacerbations During Pregnancy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39682 Fri 17 Jun 2022 15:46:08 AEST ]]>